Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229395 | 0.94 | TBXAS1 (0.62) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL27637869 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL5292390 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL27683088 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL27663546 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL5307325 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL5295951 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL21191570 | 0.93 | TBXAS1 (0.65) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| Iodide SCHEMBL27640299 | 0.93 | TBXAS1 (0.60) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL4342783 | 0.88 | TBXAS1 (0.54) | TBXAS1CYP17A1CYP19A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | TBXAS1 2328/4885CYP17A1 1291/4885CYP19A1 867/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | TBXAS1 2328/4885CYP17A1 1291/4885CYP19A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.